![Hero-Primary](/us/therapeutic-areas/oncology/dareon-5-trial/sites/default/files/2023-11/Hero-Primary_0.png)
The Dareon™-5 Trial
A clinical trial for patients with relapsed/refractory extensive-stage small-cell lung cancer or other relapsed/refractory neuroendocrine carcinomas
The DareonTM-5 trial is now enrolling patients who have relapsed/refractory extensive-stage small-cell lung cancer (SCLC) or relapsed/refractory neuroendocrine carcinomas (NECs). This is a phase 2, open label, multi-center dose-selection study of the investigational DLL3/CD3 T-cell engager, BI 764532.
Patients may be eligible to participate if they:
Are 18 years of age or older
Have relapsed/refractory SCLC, after >2 prior lines of therapy including at least one platinum-based regimen, or have relapsed/refractory extra-pulmonary NECs (excluding Merkel cell carcinoma, medullary thyroid cancer, and neuroendocrine prostate cancer) or large cell NEC of the lung, after at least one platinum-based regimen
Have at least one measurable lesion within 21 days prior to the first dose of BI 764532
Meet additional criteria
Additional inclusion and exclusion criteria apply
Share with a Colleague
Your help in creating awareness of this trial is appreciated. Click below to share this site with colleagues in your medical community:
Study information available in clinicaltrials.gov: NCT05882058
This compound is an investigational agent and has not been approved for use. The efficacy and safety of these investigational compounds have not been established.